Boston Partners lifted its holdings in Medtronic PLC (NYSE:MDT - Free Report) by 22.9% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 4,672,722 shares of the medical technology company's stock after purchasing an additional 870,606 shares during the quarter. Boston Partners owned about 0.37% of Medtronic worth $403,236,000 as of its most recent SEC filing.
Other large investors have also bought and sold shares of the company. Activest Wealth Management boosted its holdings in shares of Medtronic by 470.9% in the third quarter. Activest Wealth Management now owns 314 shares of the medical technology company's stock valued at $27,000 after buying an additional 259 shares during the period. Team Financial Group LLC acquired a new stake in shares of Medtronic during the third quarter worth $31,000. Avion Wealth raised its holdings in shares of Medtronic by 97.8% during the third quarter. Avion Wealth now owns 362 shares of the medical technology company's stock worth $31,000 after acquiring an additional 179 shares during the period. IAG Wealth Partners LLC acquired a new stake in shares of Medtronic during the second quarter worth $30,000. Finally, Pin Oak Investment Advisors Inc. bought a new stake in Medtronic in the 2nd quarter valued at $32,000. 82.06% of the stock is owned by institutional investors.
Key Headlines Impacting Medtronic
These are some of the MDT headlines that stood out recently:
Wall Street Analyst Weigh In
A number of equities analysts recently weighed in on MDT shares. Mizuho set a $115.00 target price on shares of Medtronic in a research note on Wednesday, September 2nd. BTIG Research dropped their price target on Medtronic from $100.00 to $99.00 and set a "buy" rating on the stock in a research note on Monday, October 12th. Stifel Nicolaus lifted their price target on Medtronic from $80.00 to $95.00 and gave the company a "hold" rating in a research note on Wednesday, September 2nd. TD Cowen set a $110.00 price target on Medtronic and gave the company a "buy" rating in a report on Tuesday. Finally, Wells Fargo & Company upped their price objective on Medtronic from $102.00 to $104.00 and gave the stock an "overweight" rating in a research report on Wednesday, September 2nd. Eighteen investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $103.75.
Read Our Latest Research Report on MDT
Medtronic Price Performance
NYSE:MDT opened at $100.76 on Thursday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.54 and a current ratio of 2.07. The stock's 50-day simple moving average is $94.26 and its 200 day simple moving average is $88.48. The company has a market cap of $128.89 billion, a P/E ratio of 24.82, a P/E/G ratio of 2.39 and a beta of 0.56. Medtronic PLC has a 52-week low of $73.31 and a 52-week high of $106.33.
Medtronic (NYSE:MDT - Get Free Report) last posted its quarterly earnings results on Tuesday, September 1st. The medical technology company reported $1.45 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.39 by $0.06. The firm had revenue of $9.76 billion for the quarter, compared to analyst estimates of $9.55 billion. Medtronic had a net margin of 13.93% and a return on equity of 14.78%. The company's quarterly revenue was up 13.7% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.26 earnings per share. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. As a group, sell-side analysts forecast that Medtronic PLC will post 5.98 EPS for the current fiscal year.
Insider Buying and Selling at Medtronic
In other Medtronic news, CEO Geoffrey Martha sold 50,000 shares of the stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $95.00, for a total transaction of $4,750,000.00. Following the sale, the chief executive officer directly owned 277,866 shares in the company, valued at $26,397,270. This represents a 15.25% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Marinaro sold 10,420 shares of the stock in a transaction that occurred on Thursday, October 15th. The stock was sold at an average price of $96.00, for a total transaction of $1,000,320.00. Following the sale, the executive vice president owned 105,916 shares in the company, valued at $10,167,936. This represents a 8.96% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 61,903 shares of company stock valued at $5,889,203 in the last quarter. Company insiders own 0.27% of the company's stock.
Medtronic Company Profile
(
Free Report)
Medtronic plc is a medical technology company that develops and manufactures devices and therapies for a range of health conditions. Its products include pacemakers and defibrillators, heart valves, surgical technologies, neurostimulation devices, and insulin pumps and other diabetes-management products. The company was founded in Minneapolis in 1949 by Earl Bakken and Palmer Hermundslie as a medical equipment repair business. It has since grown into a global company serving patients and health care providers in more than 150 countries.
Further Reading
Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic PLC (NYSE:MDT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Medtronic, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medtronic wasn't on the list.
While Medtronic currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.